Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates, and Treatment Opportunities Contributor(s): McIntyre, Roger S. (Editor), Cha, Danielle S. |
|
![]() |
ISBN: 1107074584 ISBN-13: 9781107074583 Publisher: Cambridge University Press OUR PRICE: $121.60 Product Type: Hardcover - Other Formats Published: April 2016 |
Additional Information |
BISAC Categories: - Medical | Mental Health - Psychology | Psychopathology - Depression - Medical | Psychiatry - General |
Dewey: 616.852 |
LCCN: 2015016410 |
Physical Information: 0.87" H x 6.39" W x 9.37" (1.71 lbs) 370 pages |
Descriptions, Reviews, Etc. |
Publisher Description: Major Depressive Disorder (MDD) is the leading cause of disability globally in both developed and developing nations. The staggering economic costs attributable to MDD are largely a consequence of impairment in role function. Evidence indicates that disturbance in the domain of cognitive function in individuals with MDD is the principle determinant of health outcome. This is the first book to comprehensively explore the domain of cognition in MDD. The literature describing cognitive dysfunction is reviewed with particular focus on clinical determinants, pathophysiology and causative factors. The patient subpopulations most susceptible are defined. A summary of contemporary assessment tools for research and clinical purposes is provided. Multimodality treatments and prevention strategies are described. This book is an invaluable resource for psychiatrists, neuropsychologists and other members of the mental health team, as well as for policy makers, vocation rehabilitation experts, disability providers and other stakeholders interested in improving health outcomes in MDD. |
Contributor Bio(s): McIntyre, Roger S.: - Roger S. McIntyre is Head of the Mood Disorders Psychopharmacology Unit, University Health Network, and Professor of Psychiatry and Pharmacology, University of Toronto, ON, Canada.Cha, Danielle S.: - Danielle S. Cha is a Researcher at the Institute of Medical Science, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada. |